🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalEU EMA compounding guidance — need advice

EU EMA compounding guidance — need advice

VanRx_Mike Mon, Oct 27, 2025 at 2:21 PM 10 replies 1,220 viewsPage 1 of 2
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
VanRx_Mike
Member
678
2,890
May 2024
Vancouver, CA
Oct 27, 2025 at 2:21 PM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

The bit I cannot resolve on my own is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material.

I would rather have one careful answer than five confident ones.

19 14Dr.LeslieOBGYN, MikeNYC_runner and 16 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Oct 27, 2025 at 4:21 PM#2

Short answer first, then the reasoning. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Last edited: Oct 27, 2025 at 9:21 PM
18 13pam_stl, wei_SG, cory_ATX and 15 others
Reply Quote Save Share Report
mia_MS2
New Member
8
23
Jun 2026
Ann Arbor, MI
Oct 27, 2025 at 6:21 PM#3
Dr.RenalNash said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

Last edited: Oct 27, 2025 at 9:21 PM
17 12dave_SLC, FDA_TrackerJim, ricardo_MIA and 14 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
MariaRD
Member
823
4,567
Jun 2024
New Mexico
Oct 27, 2025 at 8:21 PM#4
VanRx_Mike said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

This matches mine closely enough to be worth saying so. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

16 11rick_sfbay, maria_elpaso, anders_CPH and 13 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Oct 28, 2025 at 8:11 AM#5

Clinical perspective, offered as context rather than as advice.

For compounded supply users considering compounded for the first time: here's a step-by-step guide:

  1. Get a prescription from your doctor (telehealth counts)
  2. Research 503B compounding pharmacies with good community reviews
  3. Verify their FDA registration and inspection history
  4. Request a COA for your specific compound before ordering
  5. Start with a 1-month supply to test
  6. Consider sending a sample to Janoshik for independent verification
  7. Track your response compared to brand (if you were on it previously)
Last edited: Oct 28, 2025 at 1:11 PM
15 10Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 12 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register